BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Research Roundup: Alzheimer’s Research Breakthroughs Offer Potential Therapeutic Pathways

  This week, two studies provided big insights into brain changes and specific genetic sites and risk factors for Alzheimer’s disease. For those and more, continue reading.

  April 7, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Aptinyx Suffers Defeat in Diabetic Peripheral Neuropathy as Drug Fails Endpoint

  Aptinyx therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy failed to produce significant results. Here is why it happened.

  April 7, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Triana Raises $110M to Solve Undruggable Cancer Targets with Molecular Glue

  Triana Biomedicines leaped out of stealth mode with $110 million in Series A financing that will be used to fund its mission to discover and develop novel small molecules to treat diseases.

  April 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Out of Office: a Comprehensive Guide to Vacation Days and PTO (Paid Time Off)

  If your personal life has taken a backseat, it might be time to use your paid time off. Learn everything you need to know about PTO and how to request it in our guide.

  April 7, 2022

   · 

  5 min read

   · 

  Franklin Carpenter
• 

  Ten Genes Linked to Schizophrenia Risk in Possibly Transformative Research

  An article in Nature explains that ten genes, upon severe mutation that alters genetic function, are linked to an increased risk of the development of schizophrenia.

  April 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Deals

  Pfizer Bolsters RSV Position with $525 Million ReViral Buy

  Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a biotech focused on developing therapeutics that target respiratory syncytial virus (RSV).

  April 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Sunshine Biopharma’s Stock Scorches with Promising mRNA Molecules for Cancer

  Sunshine Biopharma, Inc announced this week that its novel-formulation mRNA molecules induce cancer cell death in cell cultures.

  April 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Business

  BioSpace Movers & Shakers, April 8

  Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.

  April 7, 2022

   · 

  10 min read

   · 

  Alex Keown
• 

  Business

  Jazz Howls at Immuno-Oncology Success with Werewolf Alliance (UPDATED)

  The deal marks the first immuno-oncology program for Jazz Pharma. With it, they are trying to become a leading oncology company. Here’s more about their success.

  April 7, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  AstraZeneca Picks Up Another Oncology Asset in Quest to “Completely Replace” Standard

  AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.

  April 7, 2022

   · 

  3 min read

   · 

  Hayley Shasteen